Prescription Medicines
Campex Inj.
- Product Category
- powerful pain reliever
- Active Ingredients
- tramadol hydrochloride
- Appearance
- A colorless ampoule containing a colorless and transparent liquid.
- Reimbursement Code
- 648100181
01 / 02
1. Composition and Strength
- Active ingredient: Tramadol hydrochloride (KP)----50mg
- Additives: Water for injection, sodium acetate
2. Effectiveness
Severe and moderate acute and chronic pain (various cancers, etc.), pain after diagnosis and surgery
3. Dosage and dosage
The dosage of this drug should be adjusted according to the patient's pain intensity and clinical response. Generally, the lowest dose that can relieve pain is administered.
adult
As tramadol hydrochloride, 50-100 mg at a time is administered intravenously or intramuscularly, and the injection is repeated every 4-5 hours as needed.
Up to 400 mg can be administered per day.
old man
No dose adjustment is necessary for patients under 75 years of age without clinically confirmed hepatic or renal dysfunction. In patients over 75 years of age, excretion of this drug may be delayed, so the administration interval should be adjusted if necessary.
Patients with renal dysfunction/dialysis or liver dysfunction
Since excretion of this drug may be delayed in patients with renal or hepatic dysfunction, extending the dosing interval should be considered in these patients.
4. Precautions for use
1. Warning
1) Convulsions have been reported in patients receiving recommended doses of tramadol. This risk may increase at doses exceeding the maximum recommended daily dose of 400 mg tramadol hydrochloride. Additionally, tramadol may increase the risk of seizures in patients taking other medications that lower the seizure threshold. Patients with epilepsy or seizure risk should be administered only when absolutely necessary.
2) Mental and physical dependence may occur due to intolerance due to long-term administration. For patients with drug abuse or dependence, administer for a short period of time under strict supervision.
3) Concurrent administration of tramadol and central nervous system depressants, including alcohol or benzodiazepine drugs, may cause deep sedation, respiratory depression, coma, and death. Because of these risks, co-administration of this drug and central nervous system depressants should be prescribed only for patients for whom there are no appropriate alternative treatments. If co-administration of this drug and a central nervous system depressant is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation.
4) Patients who are CYP2D6 ultrafast metabolizers may metabolize tramadol to its active metabolite (M1) more quickly and completely than other patients. This rapid metabolism may result in higher than expected serum M1 concentrations, which may increase the risk of respiratory depression. For patients known to be CYP2D6 ultrarapid metabolizers, alternative agents, dose reduction, and/or increased frequency of monitoring for signs of tramadol overdose (e.g., respiratory depression) are recommended.
5) Ultra-rapid metabolism of tramadol and another risk factor for life-threatening respiratory depression in children: Life-threatening respiratory depression and death have occurred in children administered tramadol. Some reported cases occurred after children underwent tonsillectomy and/or adenoidectomy and were demonstrated to be ultra-rapid metabolizers of tramadol due to CYP2D6 polymorphism. This drug is not administered to children under 12 years of age and children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy. This drug should be avoided in children 12 to 18 years of age who have other risk factors that increase susceptibility to the respiratory depressant effects of tramadol.
6) Ampoule injections may contain glass fragments when cutting the container, which may cause side effects, so cut them carefully to minimize glass fragments during use, but be especially careful when using them on children and the elderly.
2. Do not administer to the following patients
1) Patients with acute alcoholism
2) Patients addicted to drugs that act on the central nervous system, such as sleeping pills, painkillers, opium, and psychotropic drugs
3) Patients with severe respiratory depression (mild respiratory depression may occur)
4) Patients at risk of clouding of consciousness due to head injury or brain lesion
5) Patients receiving MAO inhibitors or patients who have taken the medication within the last 14 days
6) Patients with severe renal impairment
7) Patients with severe hepatic impairment
8) Pregnant women, lactating women
9) Children under 12 years of age
10) Post-operative management in children under 18 years of age who underwent tonsillectomy and/or adenoidectomy.
11) Patients with a history of hypersensitivity to this drug or its components or opiates
12) Epilepsy patients who are not receiving appropriate treatment
13) Use for the purpose of treating drug withdrawal symptoms
14) Patients with genetic galactose intolerance, Lapp lactase deficiency, or glucose-calactose malabsorption.
3. Administer with caution to the following patients:
1) Patients receiving concurrent or repeated administration of morphine (a mild antagonistic effect of morphine was recognized in animal experiments, so withdrawal symptoms may occur).
2) Patients with biliary disease (in animal experiments, when administered in large quantities, the sphincter of Oddi contracted).
3) Patients with hepatic impairment (there have been reports of increased serum AST and ALT activity levels in animal experiments.)
4) Drunk patient
5) Patients with hypersensitivity to opium
6) Patients with renal impairment (In renal dysfunction, the excretion rate and amount of this drug and its active metabolites are reduced, so it is recommended to reduce the dosage for patients with a creatinine clearance of less than 30ml/min.)
7) Patients receiving central nervous system depressants (alcohol, opiates, anesthetics, phenothiazine drugs, tranquilizers, sedative-hypnotics) (administer in reduced doses)
8) Patients with a history of convulsions (Convulsive seizures may occur, so observe sufficiently during administration of this drug.)
9) Although tramadol is an opiate agonist, it cannot suppress morphine withdrawal symptoms, so it is not an appropriate alternative drug for patients with drug withdrawal symptoms.
10) The risk of dependence and abuse is increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).
4. Adverse reactions
1) Seizures: Seizures may increase when taking this drug in excess of the usual dose, but there are reports that seizures occurred even at the usual dose.
The likelihood of seizures may increase in patients receiving the following drugs:
- Tricyclic antidepressants (imipramine) and other tricyclic drugs (cyclobenzaprine, promethazine, etc.)
- Selective serotonin reuptake inhibitors (SSRI antidepressants or appetite suppressants)
- MAO inhibitors
- Neuroleptics (phenothiazine, butyrophenone)
- Mefloquine
- Bupropion
- Neuroleptics
- Other drugs that reduce the seizure threshold
Additionally, the possibility of seizures may increase in patients with epilepsy, patients with a history of seizures, and patients at risk of seizures (head injury, metabolic disorders, patients with alcohol and drug withdrawal, patients with central nervous system infections).
In case of overdose of this drug, the risk of seizures may increase due to the administration of naloxone.
2) Hypersensitivity: If hypersensitivity symptoms such as shock or anaphylaxis occur, discontinue administration. There have also been reports of severe anaphylactoid symptoms (rarely fatal) when administered the first dose. Additionally, itching, hives, bronchospasm, and angioedema may occur.
3) Respiratory system: Respiratory depression may sometimes occur, so in such cases, artificial respiration (oxygen respiration if necessary) or administration of dimorpholamine is effective. Additionally, in rare cases, shortness of breath may occur. Although the general correlation has not yet been established, asthma exacerbation has been reported. Hiccups may occur, but the frequency is unknown.
4) Circulatory system: Occasionally, palpitations, coldness, nervousness, vasodilatation, decreased blood pressure, arrhythmia, and facial pallor may occur, and in rare cases, it may affect the cardiovascular system. Additionally, syncope, orthostatic hypotension, and tachycardia may occur. These adverse reactions may occur especially during intravenous administration or in patients under physical stress. Additionally, bradycardia and increased blood pressure may occur in rare cases.
5) Central nervous system: Sometimes drowsiness, sleep, headache, heaviness, excitement, tremor, tinnitus, numbness in both hands, anxiety, collapse, fatigue, weariness, sweating, dizziness, staggering, discomfort, difficulty urinating, dry mouth, dry mouth, confusion, coordination disorder, euphoria, nervousness, sleep disorder, cognitive impairment, hallucinations, forgetfulness, concentration disorder, and depression may occur. Rarely, changes in appetite, paresthesia, respiratory depression, epileptic convulsions, involuntary muscle contractions, and syncope may occur. If the recommended dose is significantly exceeded or administered concurrently with other centrally depressant drugs, respiratory depression may occur. Epileptic convulsions mainly occurred after high doses of tramadol were administered or when administered concurrently with drugs that lower the seizure threshold.
6) Digestive system: Occasionally, nausea, vomiting, abdominal distension, stomach upset, abdominal pain, loss of appetite, constipation, and dry mouth may occur. In rare cases, gastrointestinal irritation (epigastric tightness, flatulence) may occur.
7) Musculoskeletal system: Hypertonia may appear. Additionally, in rare cases, motor weakness may occur.
8) Urogenital system: Urinary retention, frequent urination, menopausal syndrome, urinary disorders, and menstrual disorders may occur.
9) Skin: Hives, vesicles, and Stevens-Johnson syndrome may appear. Commonly, sweating or less commonly, skin reactions (e.g., itching, rash, hives) may occur.
10) Dependence: This drug causes mental and physical dependence on morphine-type (μ-opium) drugs, and cases of abuse and dependence of this drug have been reported, so it is not administered to patients with opiate dependence. Physical dependence may relapse in patients with a history of dependence or chronic use of other opiates. It is advisable not to administer to patients prone to drug abuse, patients with a history of drug dependence, or patients chronically using opiates.
11) Mental illness: In rare cases, hallucinations, confusion, sleep disorders, anxiety and nightmares may occur. Psychiatric adverse reactions may occur after tramadol administration, and their severity and characteristics vary depending on the individual. (Depends on individual personality and treatment period). These reactions include changes in mood (usually euphoria, sometimes dysphoria), changes in activity (usually inhibition, sometimes augmentation), changes in cognitive and sensory abilities (e.g., decision-making, dyscognition), and may lead to dependence.
12) Hepatobiliary abnormalities: In some cases, elevated liver enzyme levels were reported during tramadol treatment.
13) Metabolic and nutritional abnormalities: Hypoglycemia may occur, but the frequency is unknown.
14) Others: Occasionally, fever, heat sensation, chills, cold sensation, hives, rash, visual impairment, taste impairment, weight loss, and irritation at the injection site (limited to injections) may occur. Fatigue may commonly occur, and rarely allergic reactions (e.g., dyspnea, bronchospasm, wheezing, angioneurotic edema) and anaphylaxis; Withdrawal symptoms similar to those experienced when opiates are discontinued may include: agitation, anxiety, irritability, insomnia, hyperkinesis, tremors, and gastrointestinal symptoms.
In very rare cases, when tramadol is discontinued, the following other symptoms may occur: panic attacks, severe anxiety, hallucinations, paresthesia, tinnitus, and abnormal central nervous system symptoms.
5. General precautions
1) When administering this drug, symptoms such as nausea, rarely vomiting, drowsiness, dizziness, and unsteadiness may occur. Therefore, when administering this drug to an outpatient, the patient must be sufficiently stabilized and then checked for safety before returning home.
2) Patients taking this drug should be careful not to engage in hazardous machinery operation, such as driving a car.
3) Do not use for minor pain.
4) When this drug is administered long-term, tolerance may develop and higher doses may be required to control pain. In this case, it is difficult to completely exclude the possibility of dependence and withdrawal symptoms when the drug is suddenly stopped, so it is advisable to gradually reduce the dose to prevent this.
5) It may lead to misdiagnosis of patients with acute abdominal diseases.
6) Life-threatening respiratory depression and death occurred in children administered tramadol. Tramadol and codeine are subject to metabolic variability based on CYP2D6 genotype, which may increase exposure to active metabolites. Post-marketing reports on tramadol or codeine suggest that children under 12 years of age may be susceptible to the respiratory depressant effects of tramadol. Children with obstructive sleep apnea who are treated with opioids for pain, especially after tonsillectomy and/or adenoidectomy, may be sensitive to respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
(4) When prescribing opioids to children, like adults, health care professionals should administer the lowest effective dose for the shortest period of time and inform patients, guardians, and caregivers about the symptoms and risks of opioid overdose.
7) Serious, life-threatening, or fatal cases in patients receiving recommended doses of tramadol.
Respiratory depression has been reported. If it is not recognized and treated promptly, it may lead to respiratory arrest and death. Management may include close observation of associated symptoms and the use of an opioid antagonist; symptoms should be treated appropriately according to the patient’s clinical condition. Carbon dioxide retention caused by respiratory depression after taking this medicine may intensify signs and symptoms of sedation.
8) Tramadol is subject to polymorphic metabolism, like codeine, in ultra-rapid metabolizers of CYP2D6 substrates exposed to potentially life-threatening levels of M1. At least one death has been reported in a nursing infant exposed to high levels of morphine in breast milk due to the mother being an extremely rapid metabolizer of codeine. Nursing infants whose mothers were ultrarapid metabolizers who administered this drug may have been exposed to potentially high levels of M1 and experienced life-threatening respiratory depression.
9) Opioid analgesics can sometimes cause reversible adrenal insufficiency requiring careful monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency include severe abdominal pain, nausea, vomiting, low blood pressure, extreme fatigue, loss of appetite, and weight loss.
9) This drug may cause opioid-induced hyperalgesia. Symptoms of opioid-induced hyperalgesia include, but are not limited to, increased pain levels with dose increases, decreased pain levels with dose decreases, or pain from stimuli that do not normally cause pain. If a patient develops these symptoms, a dose reduction or change in opioid should be carefully considered.
6. Interaction
1) Co-administration of this drug with benzodiazepines, other narcotic analgesics, general anesthetics, phenothiazine drugs, tranquilizers, sleeping pills, tricyclic antidepressants, neuromuscular blockers, or other central nervous system depressants, including alcohol, may cause additional central nervous system depressant effects and increase central nervous system depressant effects such as respiratory depression, hypotension, deep sedation, coma, or death. Therefore, when coadministered with these drugs, the dosage of one or both drugs must be reduced.
If concurrent use of this drug and a central nervous system depressant is necessary, it should be prescribed at the lowest effective dose for the shortest period of time and closely monitored for signs and symptoms of respiratory depression and sedation.
Tramadol should not be administered concomitantly with MAO inhibitors. Life-threatening drug interactions on central nervous system, respiratory, and cardiovascular functions have been observed in patients who took MAO inhibitors within 14 days prior to administration of the drug pethidine. The possibility of similar drug interactions with MAO inhibitors during tramadol treatment cannot be excluded.
2) Simultaneous or prior administration with carbamazepine (enzyme inducer) may reduce the analgesic effect of tramadol and shorten the duration of action.
3) Coumarin anticoagulants increase the international normalized ratio (INR), so caution is required when starting tramadol administration to patients taking coumarin anticoagulants.
4) When used together with quinidine, mutual adverse reactions may increase, so administer with caution.
5) There have been reports of digoxin poisoning when used in combination with digoxin, so administer with caution.
6) There are reports that co-administration with warfarin affects the effects of warfarin, such as prolonging the prothrombin time.
7) As a result of the pharmacokinetic test, there is little possibility of clinical interaction due to combined or unadministered use with cimetidine (enzyme inhibitor).
8) The analgesic effect of pure agonists such as tramadol may theoretically be reduced when administered in combination with mixed agonists/antagonists (e.g., buprenorphine, nalbuphine, pentazocine), so it is not recommended.
9) Tramadol can cause convulsions, and selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics, and drugs that lower the seizure threshold (bupropion, mirtazapine, tetrahydrocannabinol, etc.) increase the possibility of causing convulsions.
10) Serotonin syndrome has been reported when tramadol is coadministered with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors, tricyclic antidepressants (TCAs), mirtazapine, and skeletal muscle relaxants (e.g., cyclobenzaprine, metaxalone). Examples of symptoms of serotonin syndrome include: Spontaneous clonic convulsions, induced or myoclonic convulsions with anxiety or sweating, induced or myoclonic convulsions with tremors, hyperreflexia, hypertonia and fever.
Symptoms of serotonin syndrome generally improve quickly after discontinuation of the drug, and treatment should be determined based on the characteristics and severity of the symptoms.
11) Linezolid: When administered concurrently with non-selective MAO inhibitors, the risk of developing serotonin syndrome may increase. (diarrhea, tachycardia, sweating, tremor, confusion and coma)
12) Drugs known to inhibit cytochrome P3A4, such as ketoconazole and erythromycin, may inhibit tramadol metabolism (N-demethylation) and the metabolism of the active O-demethylated metabolite. The clinical significance of this interaction has not been studied.
13) A limited number of studies have shown that tramadol administration due to postoperative pain increased in patients who were administered the antiemetic drug ondansetron, a 5-HT3 antagonist, before and after surgery.
14) 50mg/ml, 100mg/2ml injections are contraindicated in combination with diclofenac, indomethacin, phenylbutazone, diazepam, flunitrazepam, midazolam, and nitroglycerin injections.
7. Administration to pregnant and lactating women
1) Animal and in vitro experiments showed mutagenicity, carcinogenicity, and reproductive toxicity, so do not administer to pregnant women or women who may be pregnant. (In animal experiments, high doses of tramadol were found to affect organ development, ossification, and neonatal death. Tramadol passes through the placenta. The safety of tramadol for pregnant women and newborns has not been proven.)
2) This drug should not be administered to nursing mothers. After a single intravenous administration of 100 mg of tramadol, the concentration accumulated in breast milk within 16 hours was 100 mcg of tramadol (0.1% of the nursing mother's dose) and 27 mcg of M1. Tramadol and its active metabolite (M1) are present in breast milk. There are no data on the effects of this drug on nursing infants or breast milk production. M1 binds to the mu-opioid receptor more strongly than tramadol. Published studies have reported tramadol administration to lactating mothers in the early postpartum period and tramadol and M1 in colostrum. Women who are ultra-rapid metabolizers of tramadol may develop higher-than-expected serum M1 levels, and these higher M1 levels in breast milk may put the nursing infant at risk. In women with normal tramadol metabolism, the amount of tramadol excreted in breast milk is low and dose-dependent. Patients should be informed of the occurrence of serious adverse reactions, including excessive sedation and respiratory depression in nursing infants, during treatment with this drug.
If a nursing infant is exposed to this drug through breast milk, monitor for the development of excessive sedation and respiratory depression. Withdrawal symptoms may occur in nursing infants if the mother stops taking opioid painkillers or stops breastfeeding.
3) Tramadol administered before or during birth does not affect uterine contractions. Short-term administration of high doses in late pregnancy may cause respiratory depression in newborns. Long-term administration during pregnancy may cause withdrawal symptoms in the newborn.
8. Administration to children
Life-threatening respiratory depression and death have occurred in children receiving tramadol. Some reported cases occurred after tonsillectomy and/or adenoidectomy, one of whom was proven to be an ultrarapid metabolizer of tramadol (e.g., multiple copies of the cytochrome P450 isoenzyme 2D6 (CYP2D6) gene). Children with sleep apnea may be particularly sensitive to respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
9. Administration to elderly people
Because plasma concentrations may increase slightly, do not administer 300 mg or more per day to patients aged 75 years or older.
10. Treatment in case of overdose
Symptoms: In case of overdose, severe respiratory depression and seizures may occur, and symptoms similar to those of other central analgesics (opioids) poisoning may occur. ; Pupil constriction, vomiting, cardiovascular collapse, coma due to loss of consciousness, convulsions, and difficulty breathing due to respiratory depression.
Treatment: Perform general first aid. Secure the airway and maintain breathing and cardiovascular function depending on symptoms. In case of oral drug overdose, induce vomiting (conscious patient) or gastric lavage. The antidote for shortness of breath is naloxone. In animal experiments, convulsions caused by overdosage of this drug with barbiturates or benzodiazepines were suppressed, but were increased by naloxone. However, pure narcotic antagonists such as naloxone do not inhibit the inhibitory effects of tramadol on MAO reuptake or serotonin release effects.
Hemodialysis is not recommended because less than 7% of this drug is removed during 4 hours of dialysis.
11. Application precautions
1) Inject avoiding the nerve travel area, and inject either left or right, or change the injection site.
2) If the patient complains of sharp pain and shows reflux of blood when inserting the needle, immediately remove the needle and change the injection site.
3) When using the same syringe as barbituric acid derivatives (injection solution), do not mix them in the same syringe as precipitation may occur.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.
5. How to save
Sealed container, stored at room temperature (1~30℃)
6. Packaging unit
1mL x 50Amp
7. Expiration date
36 months from date of manufacture
- Active ingredient: Tramadol hydrochloride (KP)----50mg
- Additives: Water for injection, sodium acetate
2. Effectiveness
Severe and moderate acute and chronic pain (various cancers, etc.), pain after diagnosis and surgery
3. Dosage and dosage
The dosage of this drug should be adjusted according to the patient's pain intensity and clinical response. Generally, the lowest dose that can relieve pain is administered.
adult
As tramadol hydrochloride, 50-100 mg at a time is administered intravenously or intramuscularly, and the injection is repeated every 4-5 hours as needed.
Up to 400 mg can be administered per day.
old man
No dose adjustment is necessary for patients under 75 years of age without clinically confirmed hepatic or renal dysfunction. In patients over 75 years of age, excretion of this drug may be delayed, so the administration interval should be adjusted if necessary.
Patients with renal dysfunction/dialysis or liver dysfunction
Since excretion of this drug may be delayed in patients with renal or hepatic dysfunction, extending the dosing interval should be considered in these patients.
4. Precautions for use
1. Warning
1) Convulsions have been reported in patients receiving recommended doses of tramadol. This risk may increase at doses exceeding the maximum recommended daily dose of 400 mg tramadol hydrochloride. Additionally, tramadol may increase the risk of seizures in patients taking other medications that lower the seizure threshold. Patients with epilepsy or seizure risk should be administered only when absolutely necessary.
2) Mental and physical dependence may occur due to intolerance due to long-term administration. For patients with drug abuse or dependence, administer for a short period of time under strict supervision.
3) Concurrent administration of tramadol and central nervous system depressants, including alcohol or benzodiazepine drugs, may cause deep sedation, respiratory depression, coma, and death. Because of these risks, co-administration of this drug and central nervous system depressants should be prescribed only for patients for whom there are no appropriate alternative treatments. If co-administration of this drug and a central nervous system depressant is decided, prescribe it at the lowest effective dose for the shortest period of time and closely monitor the patient for signs and symptoms of respiratory depression and sedation.
4) Patients who are CYP2D6 ultrafast metabolizers may metabolize tramadol to its active metabolite (M1) more quickly and completely than other patients. This rapid metabolism may result in higher than expected serum M1 concentrations, which may increase the risk of respiratory depression. For patients known to be CYP2D6 ultrarapid metabolizers, alternative agents, dose reduction, and/or increased frequency of monitoring for signs of tramadol overdose (e.g., respiratory depression) are recommended.
5) Ultra-rapid metabolism of tramadol and another risk factor for life-threatening respiratory depression in children: Life-threatening respiratory depression and death have occurred in children administered tramadol. Some reported cases occurred after children underwent tonsillectomy and/or adenoidectomy and were demonstrated to be ultra-rapid metabolizers of tramadol due to CYP2D6 polymorphism. This drug is not administered to children under 12 years of age and children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy. This drug should be avoided in children 12 to 18 years of age who have other risk factors that increase susceptibility to the respiratory depressant effects of tramadol.
6) Ampoule injections may contain glass fragments when cutting the container, which may cause side effects, so cut them carefully to minimize glass fragments during use, but be especially careful when using them on children and the elderly.
2. Do not administer to the following patients
1) Patients with acute alcoholism
2) Patients addicted to drugs that act on the central nervous system, such as sleeping pills, painkillers, opium, and psychotropic drugs
3) Patients with severe respiratory depression (mild respiratory depression may occur)
4) Patients at risk of clouding of consciousness due to head injury or brain lesion
5) Patients receiving MAO inhibitors or patients who have taken the medication within the last 14 days
6) Patients with severe renal impairment
7) Patients with severe hepatic impairment
8) Pregnant women, lactating women
9) Children under 12 years of age
10) Post-operative management in children under 18 years of age who underwent tonsillectomy and/or adenoidectomy.
11) Patients with a history of hypersensitivity to this drug or its components or opiates
12) Epilepsy patients who are not receiving appropriate treatment
13) Use for the purpose of treating drug withdrawal symptoms
14) Patients with genetic galactose intolerance, Lapp lactase deficiency, or glucose-calactose malabsorption.
3. Administer with caution to the following patients:
1) Patients receiving concurrent or repeated administration of morphine (a mild antagonistic effect of morphine was recognized in animal experiments, so withdrawal symptoms may occur).
2) Patients with biliary disease (in animal experiments, when administered in large quantities, the sphincter of Oddi contracted).
3) Patients with hepatic impairment (there have been reports of increased serum AST and ALT activity levels in animal experiments.)
4) Drunk patient
5) Patients with hypersensitivity to opium
6) Patients with renal impairment (In renal dysfunction, the excretion rate and amount of this drug and its active metabolites are reduced, so it is recommended to reduce the dosage for patients with a creatinine clearance of less than 30ml/min.)
7) Patients receiving central nervous system depressants (alcohol, opiates, anesthetics, phenothiazine drugs, tranquilizers, sedative-hypnotics) (administer in reduced doses)
8) Patients with a history of convulsions (Convulsive seizures may occur, so observe sufficiently during administration of this drug.)
9) Although tramadol is an opiate agonist, it cannot suppress morphine withdrawal symptoms, so it is not an appropriate alternative drug for patients with drug withdrawal symptoms.
10) The risk of dependence and abuse is increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).
4. Adverse reactions
1) Seizures: Seizures may increase when taking this drug in excess of the usual dose, but there are reports that seizures occurred even at the usual dose.
The likelihood of seizures may increase in patients receiving the following drugs:
- Tricyclic antidepressants (imipramine) and other tricyclic drugs (cyclobenzaprine, promethazine, etc.)
- Selective serotonin reuptake inhibitors (SSRI antidepressants or appetite suppressants)
- MAO inhibitors
- Neuroleptics (phenothiazine, butyrophenone)
- Mefloquine
- Bupropion
- Neuroleptics
- Other drugs that reduce the seizure threshold
Additionally, the possibility of seizures may increase in patients with epilepsy, patients with a history of seizures, and patients at risk of seizures (head injury, metabolic disorders, patients with alcohol and drug withdrawal, patients with central nervous system infections).
In case of overdose of this drug, the risk of seizures may increase due to the administration of naloxone.
2) Hypersensitivity: If hypersensitivity symptoms such as shock or anaphylaxis occur, discontinue administration. There have also been reports of severe anaphylactoid symptoms (rarely fatal) when administered the first dose. Additionally, itching, hives, bronchospasm, and angioedema may occur.
3) Respiratory system: Respiratory depression may sometimes occur, so in such cases, artificial respiration (oxygen respiration if necessary) or administration of dimorpholamine is effective. Additionally, in rare cases, shortness of breath may occur. Although the general correlation has not yet been established, asthma exacerbation has been reported. Hiccups may occur, but the frequency is unknown.
4) Circulatory system: Occasionally, palpitations, coldness, nervousness, vasodilatation, decreased blood pressure, arrhythmia, and facial pallor may occur, and in rare cases, it may affect the cardiovascular system. Additionally, syncope, orthostatic hypotension, and tachycardia may occur. These adverse reactions may occur especially during intravenous administration or in patients under physical stress. Additionally, bradycardia and increased blood pressure may occur in rare cases.
5) Central nervous system: Sometimes drowsiness, sleep, headache, heaviness, excitement, tremor, tinnitus, numbness in both hands, anxiety, collapse, fatigue, weariness, sweating, dizziness, staggering, discomfort, difficulty urinating, dry mouth, dry mouth, confusion, coordination disorder, euphoria, nervousness, sleep disorder, cognitive impairment, hallucinations, forgetfulness, concentration disorder, and depression may occur. Rarely, changes in appetite, paresthesia, respiratory depression, epileptic convulsions, involuntary muscle contractions, and syncope may occur. If the recommended dose is significantly exceeded or administered concurrently with other centrally depressant drugs, respiratory depression may occur. Epileptic convulsions mainly occurred after high doses of tramadol were administered or when administered concurrently with drugs that lower the seizure threshold.
6) Digestive system: Occasionally, nausea, vomiting, abdominal distension, stomach upset, abdominal pain, loss of appetite, constipation, and dry mouth may occur. In rare cases, gastrointestinal irritation (epigastric tightness, flatulence) may occur.
7) Musculoskeletal system: Hypertonia may appear. Additionally, in rare cases, motor weakness may occur.
8) Urogenital system: Urinary retention, frequent urination, menopausal syndrome, urinary disorders, and menstrual disorders may occur.
9) Skin: Hives, vesicles, and Stevens-Johnson syndrome may appear. Commonly, sweating or less commonly, skin reactions (e.g., itching, rash, hives) may occur.
10) Dependence: This drug causes mental and physical dependence on morphine-type (μ-opium) drugs, and cases of abuse and dependence of this drug have been reported, so it is not administered to patients with opiate dependence. Physical dependence may relapse in patients with a history of dependence or chronic use of other opiates. It is advisable not to administer to patients prone to drug abuse, patients with a history of drug dependence, or patients chronically using opiates.
11) Mental illness: In rare cases, hallucinations, confusion, sleep disorders, anxiety and nightmares may occur. Psychiatric adverse reactions may occur after tramadol administration, and their severity and characteristics vary depending on the individual. (Depends on individual personality and treatment period). These reactions include changes in mood (usually euphoria, sometimes dysphoria), changes in activity (usually inhibition, sometimes augmentation), changes in cognitive and sensory abilities (e.g., decision-making, dyscognition), and may lead to dependence.
12) Hepatobiliary abnormalities: In some cases, elevated liver enzyme levels were reported during tramadol treatment.
13) Metabolic and nutritional abnormalities: Hypoglycemia may occur, but the frequency is unknown.
14) Others: Occasionally, fever, heat sensation, chills, cold sensation, hives, rash, visual impairment, taste impairment, weight loss, and irritation at the injection site (limited to injections) may occur. Fatigue may commonly occur, and rarely allergic reactions (e.g., dyspnea, bronchospasm, wheezing, angioneurotic edema) and anaphylaxis; Withdrawal symptoms similar to those experienced when opiates are discontinued may include: agitation, anxiety, irritability, insomnia, hyperkinesis, tremors, and gastrointestinal symptoms.
In very rare cases, when tramadol is discontinued, the following other symptoms may occur: panic attacks, severe anxiety, hallucinations, paresthesia, tinnitus, and abnormal central nervous system symptoms.
5. General precautions
1) When administering this drug, symptoms such as nausea, rarely vomiting, drowsiness, dizziness, and unsteadiness may occur. Therefore, when administering this drug to an outpatient, the patient must be sufficiently stabilized and then checked for safety before returning home.
2) Patients taking this drug should be careful not to engage in hazardous machinery operation, such as driving a car.
3) Do not use for minor pain.
4) When this drug is administered long-term, tolerance may develop and higher doses may be required to control pain. In this case, it is difficult to completely exclude the possibility of dependence and withdrawal symptoms when the drug is suddenly stopped, so it is advisable to gradually reduce the dose to prevent this.
5) It may lead to misdiagnosis of patients with acute abdominal diseases.
6) Life-threatening respiratory depression and death occurred in children administered tramadol. Tramadol and codeine are subject to metabolic variability based on CYP2D6 genotype, which may increase exposure to active metabolites. Post-marketing reports on tramadol or codeine suggest that children under 12 years of age may be susceptible to the respiratory depressant effects of tramadol. Children with obstructive sleep apnea who are treated with opioids for pain, especially after tonsillectomy and/or adenoidectomy, may be sensitive to respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
(4) When prescribing opioids to children, like adults, health care professionals should administer the lowest effective dose for the shortest period of time and inform patients, guardians, and caregivers about the symptoms and risks of opioid overdose.
7) Serious, life-threatening, or fatal cases in patients receiving recommended doses of tramadol.
Respiratory depression has been reported. If it is not recognized and treated promptly, it may lead to respiratory arrest and death. Management may include close observation of associated symptoms and the use of an opioid antagonist; symptoms should be treated appropriately according to the patient’s clinical condition. Carbon dioxide retention caused by respiratory depression after taking this medicine may intensify signs and symptoms of sedation.
8) Tramadol is subject to polymorphic metabolism, like codeine, in ultra-rapid metabolizers of CYP2D6 substrates exposed to potentially life-threatening levels of M1. At least one death has been reported in a nursing infant exposed to high levels of morphine in breast milk due to the mother being an extremely rapid metabolizer of codeine. Nursing infants whose mothers were ultrarapid metabolizers who administered this drug may have been exposed to potentially high levels of M1 and experienced life-threatening respiratory depression.
9) Opioid analgesics can sometimes cause reversible adrenal insufficiency requiring careful monitoring and glucocorticoid replacement therapy. Symptoms of acute or chronic adrenal insufficiency include severe abdominal pain, nausea, vomiting, low blood pressure, extreme fatigue, loss of appetite, and weight loss.
9) This drug may cause opioid-induced hyperalgesia. Symptoms of opioid-induced hyperalgesia include, but are not limited to, increased pain levels with dose increases, decreased pain levels with dose decreases, or pain from stimuli that do not normally cause pain. If a patient develops these symptoms, a dose reduction or change in opioid should be carefully considered.
6. Interaction
1) Co-administration of this drug with benzodiazepines, other narcotic analgesics, general anesthetics, phenothiazine drugs, tranquilizers, sleeping pills, tricyclic antidepressants, neuromuscular blockers, or other central nervous system depressants, including alcohol, may cause additional central nervous system depressant effects and increase central nervous system depressant effects such as respiratory depression, hypotension, deep sedation, coma, or death. Therefore, when coadministered with these drugs, the dosage of one or both drugs must be reduced.
If concurrent use of this drug and a central nervous system depressant is necessary, it should be prescribed at the lowest effective dose for the shortest period of time and closely monitored for signs and symptoms of respiratory depression and sedation.
Tramadol should not be administered concomitantly with MAO inhibitors. Life-threatening drug interactions on central nervous system, respiratory, and cardiovascular functions have been observed in patients who took MAO inhibitors within 14 days prior to administration of the drug pethidine. The possibility of similar drug interactions with MAO inhibitors during tramadol treatment cannot be excluded.
2) Simultaneous or prior administration with carbamazepine (enzyme inducer) may reduce the analgesic effect of tramadol and shorten the duration of action.
3) Coumarin anticoagulants increase the international normalized ratio (INR), so caution is required when starting tramadol administration to patients taking coumarin anticoagulants.
4) When used together with quinidine, mutual adverse reactions may increase, so administer with caution.
5) There have been reports of digoxin poisoning when used in combination with digoxin, so administer with caution.
6) There are reports that co-administration with warfarin affects the effects of warfarin, such as prolonging the prothrombin time.
7) As a result of the pharmacokinetic test, there is little possibility of clinical interaction due to combined or unadministered use with cimetidine (enzyme inhibitor).
8) The analgesic effect of pure agonists such as tramadol may theoretically be reduced when administered in combination with mixed agonists/antagonists (e.g., buprenorphine, nalbuphine, pentazocine), so it is not recommended.
9) Tramadol can cause convulsions, and selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), antipsychotics, and drugs that lower the seizure threshold (bupropion, mirtazapine, tetrahydrocannabinol, etc.) increase the possibility of causing convulsions.
10) Serotonin syndrome has been reported when tramadol is coadministered with serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAO inhibitors, tricyclic antidepressants (TCAs), mirtazapine, and skeletal muscle relaxants (e.g., cyclobenzaprine, metaxalone). Examples of symptoms of serotonin syndrome include: Spontaneous clonic convulsions, induced or myoclonic convulsions with anxiety or sweating, induced or myoclonic convulsions with tremors, hyperreflexia, hypertonia and fever.
Symptoms of serotonin syndrome generally improve quickly after discontinuation of the drug, and treatment should be determined based on the characteristics and severity of the symptoms.
11) Linezolid: When administered concurrently with non-selective MAO inhibitors, the risk of developing serotonin syndrome may increase. (diarrhea, tachycardia, sweating, tremor, confusion and coma)
12) Drugs known to inhibit cytochrome P3A4, such as ketoconazole and erythromycin, may inhibit tramadol metabolism (N-demethylation) and the metabolism of the active O-demethylated metabolite. The clinical significance of this interaction has not been studied.
13) A limited number of studies have shown that tramadol administration due to postoperative pain increased in patients who were administered the antiemetic drug ondansetron, a 5-HT3 antagonist, before and after surgery.
14) 50mg/ml, 100mg/2ml injections are contraindicated in combination with diclofenac, indomethacin, phenylbutazone, diazepam, flunitrazepam, midazolam, and nitroglycerin injections.
7. Administration to pregnant and lactating women
1) Animal and in vitro experiments showed mutagenicity, carcinogenicity, and reproductive toxicity, so do not administer to pregnant women or women who may be pregnant. (In animal experiments, high doses of tramadol were found to affect organ development, ossification, and neonatal death. Tramadol passes through the placenta. The safety of tramadol for pregnant women and newborns has not been proven.)
2) This drug should not be administered to nursing mothers. After a single intravenous administration of 100 mg of tramadol, the concentration accumulated in breast milk within 16 hours was 100 mcg of tramadol (0.1% of the nursing mother's dose) and 27 mcg of M1. Tramadol and its active metabolite (M1) are present in breast milk. There are no data on the effects of this drug on nursing infants or breast milk production. M1 binds to the mu-opioid receptor more strongly than tramadol. Published studies have reported tramadol administration to lactating mothers in the early postpartum period and tramadol and M1 in colostrum. Women who are ultra-rapid metabolizers of tramadol may develop higher-than-expected serum M1 levels, and these higher M1 levels in breast milk may put the nursing infant at risk. In women with normal tramadol metabolism, the amount of tramadol excreted in breast milk is low and dose-dependent. Patients should be informed of the occurrence of serious adverse reactions, including excessive sedation and respiratory depression in nursing infants, during treatment with this drug.
If a nursing infant is exposed to this drug through breast milk, monitor for the development of excessive sedation and respiratory depression. Withdrawal symptoms may occur in nursing infants if the mother stops taking opioid painkillers or stops breastfeeding.
3) Tramadol administered before or during birth does not affect uterine contractions. Short-term administration of high doses in late pregnancy may cause respiratory depression in newborns. Long-term administration during pregnancy may cause withdrawal symptoms in the newborn.
8. Administration to children
Life-threatening respiratory depression and death have occurred in children receiving tramadol. Some reported cases occurred after tonsillectomy and/or adenoidectomy, one of whom was proven to be an ultrarapid metabolizer of tramadol (e.g., multiple copies of the cytochrome P450 isoenzyme 2D6 (CYP2D6) gene). Children with sleep apnea may be particularly sensitive to respiratory depressant effects. The risk for life-threatening respiratory depression and death is as follows:
(1) This drug is not administered to children under 12 years of age.
(2) This drug is not administered for post-operative management to children under 18 years of age who have undergone tonsillectomy and/or adenoidectomy.
(3) Avoid administering this drug to adolescents aged 12 to 18 years who have other risk factors that increase sensitivity to the respiratory depressant effects of tramadol, except in cases where the benefits are judged to outweigh the risks. Risk factors include conditions associated with respiratory depression, such as postoperative conditions, obstructive sleep apnea, obesity, significant pulmonary disease, neuromuscular disease, and concomitant use of other drugs that cause respiratory depression.
9. Administration to elderly people
Because plasma concentrations may increase slightly, do not administer 300 mg or more per day to patients aged 75 years or older.
10. Treatment in case of overdose
Symptoms: In case of overdose, severe respiratory depression and seizures may occur, and symptoms similar to those of other central analgesics (opioids) poisoning may occur. ; Pupil constriction, vomiting, cardiovascular collapse, coma due to loss of consciousness, convulsions, and difficulty breathing due to respiratory depression.
Treatment: Perform general first aid. Secure the airway and maintain breathing and cardiovascular function depending on symptoms. In case of oral drug overdose, induce vomiting (conscious patient) or gastric lavage. The antidote for shortness of breath is naloxone. In animal experiments, convulsions caused by overdosage of this drug with barbiturates or benzodiazepines were suppressed, but were increased by naloxone. However, pure narcotic antagonists such as naloxone do not inhibit the inhibitory effects of tramadol on MAO reuptake or serotonin release effects.
Hemodialysis is not recommended because less than 7% of this drug is removed during 4 hours of dialysis.
11. Application precautions
1) Inject avoiding the nerve travel area, and inject either left or right, or change the injection site.
2) If the patient complains of sharp pain and shows reflux of blood when inserting the needle, immediately remove the needle and change the injection site.
3) When using the same syringe as barbituric acid derivatives (injection solution), do not mix them in the same syringe as precipitation may occur.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.
5. How to save
Sealed container, stored at room temperature (1~30℃)
6. Packaging unit
1mL x 50Amp
7. Expiration date
36 months from date of manufacture
Product Updates
Total 10items